Paul Ehrlich's magic bullet concept: 100 years of progress

被引：924
作者：
Strebhardt, Klaus [1 ]
Ullrich, Axel [2 ]
机构：
[1] Univ Frankfurt Klinikum, Sch Med, Dept Obstet & Gynaecol, D-60590 Frankfurt, Germany
[2] Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany
来源：
NATURE REVIEWS CANCER | 2008年 / 8卷 / 06期
关键词：
D O I：
10.1038/nrc2394
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Exceptional advances in molecular biology and genetic research have expedited cancer drug development tremendously. The declared paradigm is the development of 'personalized and tailored drugs' that precisely target the specific molecular defects of a cancer patient. it is therefore appropriate to revisit the intellectual foundations of the development of such agents, as many have shown great clinical success. One hundred years ago, Paul Ehrlich, the founder of chemotherapy, received the Nobel Prize for Physiology or Medicine. His postulate of creating 'magic bullets' for use in the fight against human diseases inspired generations of scientists to devise powerful molecular cancer therapeutics.
引用
收藏
页码：473 / 480
页数：8
相关论文
共 162 条
  • [1] Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy
    Arons, Evgeny
    Sorbara, Lynn
    Raffeld, Mark
    Stetler-Stevenson, Maryalice
    Steinberg, Seth M.
    Liewehr, David J.
    Pastan, Ira
    Kreitman, Robert J.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (09) : 1100 - 1110
  • [2] Valproic acid (VPA) in patients with refractory advanced cancer:: a dose escalating phase I clinical trial
    Atmaca, A.
    Al-Batran, S-E
    Maurer, A.
    Neumann, A.
    Heinzel, T.
    Hentsch, B.
    Schwarz, S. E.
    Hovelmann, S.
    Goettlicher, M.
    Knuth, A.
    Jaeger, E.
    [J]. BRITISH JOURNAL OF CANCER, 2007, 97 (02) : 177 - 182
  • [3] Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL
    Azam, M
    Latek, RR
    Daley, GQ
    [J]. CELL, 2003, 112 (06) : 831 - 843
  • [4] Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors:: A pediatric oncology experimental therapeutics investigators consortium study
    Bagatell, Rochelle
    Gore, Lia
    Egorin, Merrill J.
    Ho, Richard
    Heller, Glenn
    Boucher, Nichole
    Zuhowski, Eleanor G.
    Whitlock, James A.
    Hunger, Stephen P.
    Narendran, Aru
    Katzenstein, Howard M.
    Arceci, Robert J.
    Boklan, Jessica
    Herzog, Cynthia E.
    Whitesell, Luke
    Ivy, S. Percy
    Trippett, Tanya M.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (06) : 1783 - 1788
  • [5] Adapting proteostasis for disease intervention
    Balch, William E.
    Morimoto, Richard I.
    Dillin, Andrew
    Kelly, Jeffery W.
    [J]. SCIENCE, 2008, 319 (5865) : 916 - 919
  • [6] Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK
    Barnett, David
    Stevens, Andrew
    Longson, Carole
    [J]. LANCET ONCOLOGY, 2006, 7 (10) : 807 - 808
  • [7] TRANSLOCATION OF C-ABL ONCOGENE CORRELATES WITH THE PRESENCE OF A PHILADELPHIA-CHROMOSOME IN CHRONIC MYELOCYTIC-LEUKEMIA
    BARTRAM, CR
    DEKLEIN, A
    HAGEMEIJER, A
    VANAGTHOVEN, T
    VANKESSEL, AG
    BOOTSMA, D
    GROSVELD, G
    FERGUSONSMITH, MA
    DAVIES, T
    STONE, M
    HEISTERKAMP, N
    STEPHENSON, JR
    GROFFEN, J
    [J]. NATURE, 1983, 306 (5940) : 277 - 280
  • [8] BAUMLER E, 1997, FORSCHER LEBEN
  • [9] Genetically engineered models have advantages over xenografts for preclinical studies
    Becher, OJ
    Holland, EC
    [J]. CANCER RESEARCH, 2006, 66 (07) : 3355 - 3358
  • [10] BECHER OJ, 2006, CANCER RES, P3358
12345678910